The Evidence Gap in Nutraceuticals: Why International Companies Are Turning to India to Close It

The global nutraceutical market is under growing pressure to prove itself.

In the US, the FTC and FDA have both intensified scrutiny of health claims that lack adequate clinical substantiation. In the EU, the Health Claims Regulation has already forced a reckoning — rejecting the majority of botanical health claims submitted for authorization on the grounds that the evidence base was insufficient. In Australia, the TGA's framework for listed medicines is evolving toward higher evidentiary expectations. In the UK, post-Brexit regulatory divergence is creating new compliance questions for companies operating across both markets.

The message from regulators across every major market is consistent: the era of marketing nutraceutical products on plausibility, tradition, and in-vitro data alone is ending. Clinical evidence — rigorous, human, controlled — is becoming the price of admission to credible market positioning.

For international nutraceutical companies facing this reality, the question is not whether to generate clinical evidence. It is how to do it efficiently, credibly, and at a cost that makes commercial sense. Increasingly, the answer points to India.

The Evidence Gap: What It Is and Why It Persists

The evidence gap in nutraceuticals is not a scientific problem. It is a structural and economic one — and understanding its roots is essential to understanding why it has persisted so long and what it actually takes to close it.

Regulatory requirements in most markets allow nutraceutical products to be marketed with structure/function claims — statements about how an ingredient supports normal body function — on the basis of general scientific consensus rather than product-specific clinical trials. This is a fundamentally lower bar than what is required for pharmaceutical drugs, and it has created an industry where the commercial incentive to generate rigorous clinical evidence is substantially reduced when the regulatory pathway does not require it.

The result is a market where consumer spending on nutraceuticals globally exceeds USD 400 billion annually — yet the clinical evidence base for most products on those shelves is thin, dated, or of poor methodological quality. Open-label studies. Underpowered randomized trials. In-vitro data extrapolated to human claims. Animal studies cited in support of human health benefits. Published research conducted in populations, formulations, and doses that bear little resemblance to the commercial product being sold.

This is changing — driven by regulatory tightening, by retailer and payer demands for evidence-backed products, by increasingly sophisticated consumers, and by a competitive dynamic in which clinical evidence is becoming a genuine differentiator rather than an optional investment.

The companies that are ahead of this curve — building rigorous clinical evidence now, before regulatory requirements make it mandatory — are the ones that will own the most defensible market positions in the next decade. And many of them are conducting those studies in India.

Why India Has Become a Strategic Destination for Nutraceutical Clinical Research

India's emergence as a global hub for clinical research has been well documented in the pharmaceutical context. What is less widely appreciated is how well-suited India's clinical research infrastructure is for nutraceutical and dietary supplement studies specifically — and how significant the advantages are for international sponsors who choose to conduct their studies there.

Cost Efficiency That Changes the Business Case

The cost of conducting a randomized controlled trial for a nutraceutical product in the US or Western Europe is substantial — often ranging from USD 500,000 to several million dollars depending on the indication, the endpoint, the sample size, and the study duration. At these price points, the return-on-investment calculation for clinical evidence generation is challenging, particularly for companies with diverse product portfolios and limited R&D budgets.

In India, the same study — designed to the same scientific and regulatory standards, generating data acceptable to US FDA, EMA, and TGA — can typically be conducted at 30 to 50 percent of the cost of an equivalent Western study. This is not a function of lower quality. It reflects lower site costs, lower investigator fees, lower participant compensation requirements, and a highly competitive and experienced CRO market. The cost differential is large enough to change the business case for clinical evidence generation entirely — turning studies that were financially marginal in a Western context into commercially viable investments.

For companies with multiple ingredients or products requiring clinical substantiation, this cost advantage compounds significantly. A budget that might support one or two studies in the US can support four or five studies of equivalent quality in India — accelerating the pace of evidence generation and the breadth of the clinical portfolio.

A Patient Population of Unique Scientific Value

India's population of 1.4 billion people represents a clinical research asset of exceptional diversity. For nutraceutical studies, this diversity is scientifically valuable in ways that go beyond simple recruitment efficiency.

India's disease burden in metabolic conditions — type 2 diabetes, dyslipidemia, obesity, metabolic syndrome — is among the highest in the world, and these populations are highly relevant for nutraceutical ingredients targeting metabolic health. India has large populations with documented micronutrient insufficiencies — vitamin D, iron, folate, omega-3 fatty acids — making it an ideal setting for studies of nutritional intervention in deficient populations, where effect sizes are likely to be larger and more clinically meaningful than in well-nourished Western populations.

For herbal and botanical ingredients with origins in traditional Indian medicine — ashwagandha, turmeric, tulsi, boswellia, triphala — India offers the additional advantage of a population with cultural familiarity and established patterns of use, enabling more naturalistic recruitment for studies that require participants with prior experience or acceptance of botanical products.

And from a genetic diversity standpoint, India's population represents multiple distinct ancestral groups with meaningful differences in drug metabolism, nutrient absorption, and inflammatory biology — making studies conducted in Indian populations scientifically informative for global populations in ways that studies conducted in homogeneous Western cohorts are not.

Speed: From Protocol to Data Faster Than Western Alternatives

Clinical trial timelines in the US and EU have been extending steadily — driven by increasing regulatory complexity, site activation delays, competition for experienced investigators, and patient recruitment challenges in increasingly trial-saturated healthcare environments.

India offers a meaningfully faster operating environment for nutraceutical studies. Ethics committee approvals for nutraceutical studies — which do not require the full CDSCO clinical trial approval process that pharmaceutical studies demand — can be obtained in four to eight weeks at experienced sites. Healthy volunteer recruitment for studies requiring general population participants is substantially faster than in Western markets, where participant registries are often oversubscribed and screening-to-enrolment ratios are high. Patient recruitment for condition-specific studies benefits from India's high disease prevalence in relevant therapeutic areas and from a population that is generally more willing to participate in clinical research.

For international sponsors operating under competitive pressure — where being first to market with a clinically substantiated claim is a commercial advantage — the timeline difference between conducting a study in India versus in the US or EU can be measured in months. In nutraceutical categories where competitive differentiation is intense and product lifecycles are relatively short, those months matter.

What International Sponsors Need to Know About Conducting Studies in India

The decision to conduct a nutraceutical study in India is strategically sound — but it requires a clear understanding of the operational and regulatory considerations that govern how those studies are designed and conducted.

Regulatory Acceptability: Will the Data Be Accepted at Home?

The most important question for any international sponsor considering an India-based study is whether the data generated will be accepted by their home regulator. The answer, for studies conducted to appropriate standards, is yes — but the conditions matter.

The US FDA, EMA, TGA, and Health Canada all accept clinical trial data generated outside their jurisdictions, provided the study was conducted in accordance with ICH Good Clinical Practice (GCP) guidelines, the data is complete and verifiable, and the study design meets the scientific requirements applicable to the claim being made. India has been an ICH observer and has progressively aligned its clinical research regulatory framework with ICH standards — meaning studies conducted at experienced, GCP-compliant Indian sites under appropriate oversight generate data that is internationally acceptable.

The critical variables are site selection and CRO quality. A study conducted at a well-qualified Indian site, managed by an experienced CRO with international regulatory submission experience, will generate data that stands up to regulatory scrutiny in the US, EU, and Australia. A study conducted at an inadequately qualified site, or without the quality oversight that international submissions require, will not — regardless of where it was conducted.

Ethics and Participant Protection

International sponsors sometimes have concerns about participant protection standards in India relative to their home markets. These concerns, while understandable, are increasingly misplaced for studies conducted at established, well-regulated sites.

Ethics committee oversight in India has strengthened considerably over the past decade. The New Drugs and Clinical Trials Rules, 2019 have introduced more rigorous requirements for ethics committee registration, review processes, and ongoing oversight. Informed consent requirements are comprehensive and include specific provisions for vulnerable populations, audio-visual documentation of the consent process in certain cases, and independent witness requirements.

For nutraceutical studies — which typically enroll healthy volunteers or mildly affected populations rather than severely ill patients — the ethical complexity is generally manageable, and the protections available at well-qualified Indian sites are entirely consistent with international standards.

Finding the Right CRO Partner

For international sponsors, the CRO partner is the most consequential decision in the conduct of an India-based study. The CRO is responsible not just for operational execution — recruitment, site management, data collection — but for ensuring that the study meets the scientific and regulatory standards required for international submission, for managing the interface between Indian regulatory requirements and the sponsor's home market requirements, and for producing a clinical study report that will withstand scrutiny from regulators who may be unfamiliar with the Indian clinical research environment.

The right CRO partner has demonstrable experience with internationally sponsored nutraceutical and clinical studies, a quality management system that meets ICH GCP requirements, bioanalytical capabilities or established partnerships with accredited laboratories, and a track record of producing clinical study reports that have been accepted by international regulatory authorities.

The Competitive Advantage of Acting Now

The regulatory trajectory across all major nutraceutical markets is toward higher evidentiary standards. Companies that are generating rigorous clinical evidence now — using India's cost, population, and speed advantages to build a clinical portfolio that competitors without that evidence cannot match — are positioning themselves for durable competitive advantage.

The nutraceutical companies that will define the next decade of the industry are not necessarily the ones with the best formulations. They are the ones with the best evidence — evidence generated efficiently, rigorously, and in a way that stands up to the increasing scrutiny of regulators, retailers, and consumers in every major market.

India offers the infrastructure, the population, the cost structure, and the regulatory framework to make that evidence generation not just feasible, but strategically compelling. The window for first-mover advantage in evidence-based nutraceutical positioning is open — but it will not stay open indefinitely.

At Genelife Clinical Research, we work with international nutraceutical and dietary supplement companies to design and execute clinical studies in India that meet the evidentiary standards of US, EU, Australian, and Canadian regulators. From study design and ethics committee navigation through clinical execution, bioanalytical coordination, and clinical study report preparation, we provide the end-to-end support that international sponsors need to generate evidence that works in their home markets — at a fraction of the cost of conducting the same study in the West.

---

To learn more about Genelife's international nutraceutical clinical research services, visit genelifecr.com.

Related Insights

Nutraceutical & Herbal Strategy
The Clinical Trial Process in India
How to Choose a CRO in India

Drug–Device Combination Products: Revisiting the Challenges, Thirteen Years On

In June 2012, we published a perspective on the challenges of drug–device combination products — a field that was then considered promising but operationally complex. Thirteen years later, the landscape has changed so fundamentally that the original question — whether the benefits justify the challenges — deserves a thorough revisit.

---

Where We Started

In 2012, our assessment was cautiously optimistic. The core argument was straightforward: merging pharmaceutical and medical device disciplines offered real clinical and commercial advantages, but the regulatory, engineering, and quality challenges were substantial — particularly around the question of whether drug and device manufacturing could realistically operate within a shared facility. 

Our conclusion then was that "when weighing risks and challenges against benefits, the homeostasis shifts towards the merger." The manufacturing model we favored was two distinct facilities — separate but coordinated — as the most viable approach for managing divergent regulatory and engineering requirements.

That conclusion still holds. But almost everything around it has changed.

The products themselves are more sophisticated. The regulatory frameworks governing them are more demanding, more harmonized, and more globally interconnected. The manufacturing and quality expectations have risen substantially. And an entirely new dimension — digital health and connected devices — has introduced a category of complexity that did not meaningfully exist in 2012.

What follows is an honest reassessment of where the field stands today, what has evolved, and what it means for organizations navigating this space.

The Products Have Changed

In 2012, the primary examples of drug–device combination products were relatively straightforward: drug-eluting stents, prefilled syringes, inhalers, nebulizers, some orthopedic implants. The integration of drug and device was largely mechanical — a physical delivery system for a pharmaceutical agent.

Today, the category has expanded into territory that was largely conceptual in 2012. Wearable injectors that deliver large-volume biologics subcutaneously over hours. Smart inhalers that track adherence in real time and transmit data to healthcare providers. Autoinjectors with electronic feedback mechanisms. Implantable devices with drug-eluting components designed for controlled, sustained release over months or years.

The clinical ambition of combination products has grown alongside their technical sophistication. These are no longer primarily cost-reduction or convenience plays — they are integral to the therapeutic strategy in oncology, autoimmune disease, diabetes, rare disorders, and chronic pain management. The device is not incidental to the drug; in many cases, it is inseparable from the drug's clinical effectiveness.

This expansion of scope has amplified every challenge we identified in 2012 — and created several new ones.

Regulatory Complexity: More Demanding, More Harmonized, More Consequential

In 2012, the regulatory landscape for combination products was fragmented and, in many jurisdictions, still developing. The US FDA had frameworks in place, but global harmonization was limited. In India, combination product regulation was nascent.

The past decade has brought significant change on both fronts.

Primary Mode of Action (PMOA) determination has become a foundational regulatory question — and a contentious one. Whether a combination product is primarily regulated as a drug or as a device determines the regulatory pathway, the applicable quality standards, and the agency or directorate that leads the review. For products where the drug and device components interact dynamically, this determination is rarely straightforward. Getting it wrong has compounding consequences throughout the product lifecycle.

Human factors engineering (HFE) and usability studies are now mandatory requirements, not optional considerations. Regulators — including the US FDA and EMA — expect sponsors to demonstrate not just that a combination product is safe and efficacious, but that it can be used correctly by its intended users under realistic conditions. This means structured formative and summative usability studies, root cause analysis of use errors, and design iteration based on user feedback. For self-administration devices like autoinjectors and prefilled pens — where the consequence of a use error may be a missed dose of a biologic or an accidental needle stick — this is a genuinely demanding evidentiary standard.

Cybersecurity has emerged as an entirely new regulatory dimension. For digitally integrated combination products — connected inhalers, wearable drug delivery systems, implantable devices with software components — regulators now expect cybersecurity risk assessments, secure design practices, and post-market surveillance for software vulnerabilities. The US FDA's guidance on cybersecurity in medical devices has evolved considerably, and the EU MDR has introduced requirements that push in the same direction. In 2012, this was not a consideration. Today, it is a regulatory necessity for a growing proportion of combination products.

Post-market surveillance expectations have intensified. Both the EU MDR and the FDA's evolving frameworks require proactive, systematic post-market surveillance — not just passive adverse event reporting. Real-world evidence from clinical practice is increasingly expected to feed back into benefit-risk assessments over the product lifecycle. This places ongoing operational demands on manufacturers that extend well beyond the approval milestone.

In India, the regulatory framework for combination products has been slower to formalize, but the direction of travel is clear: increasing alignment with US FDA and EU MDR principles, greater scrutiny at the approval stage, and growing expectations around post-market data generation.

Quality Management: The Hybrid QMS Challenge

In 2012, we identified quality management as one of the areas of greatest stress in a combined drug–device organization. The challenge was structural: pharmaceutical quality systems (GMP) and medical device quality systems (ISO 13485, then the FDA's Quality System Regulation) were designed independently, for different product types, with different documentation philosophies and different approaches to validation and design control.

That structural challenge has not gone away. If anything, it has intensified.

The FDA's transition from the legacy Quality System Regulation (21 CFR Part 820) to alignment with ISO 13485 has moved the regulatory goalposts for device manufacturers — and created additional complexity for organizations that must simultaneously maintain GMP compliance for their pharmaceutical components. These two quality systems are not designed to be merged; they must be operated in parallel, with deliberate integration at the points where drug and device development and manufacturing intersect.

The practical implications are significant. Design controls — a device QMS requirement — must be applied to the device component of a combination product, including design history files, design verification and validation, and risk management under ISO 14971. Process validation — a GMP requirement — must be applied to the pharmaceutical component. Where the two components interact, both sets of requirements apply simultaneously. Managing this without gaps, overlaps, or contradictions requires quality professionals who are genuinely fluent in both domains — a capability that remains in short supply.

Modern practice has responded with digital QMS platforms that can manage documentation, change control, and compliance tracking across both frameworks from a single system. These platforms reduce the risk of version control errors and compliance gaps, but they do not eliminate the underlying complexity of operating under two regulatory paradigms simultaneously.

Engineering and Manufacturing: The Two-Facility Model Validated

Our 2012 recommendation — that operating drug and device manufacturing in two distinct facilities was the more viable model — has been validated by industry practice over the intervening decade. The "two-facility" or "segregated but integrated" model is now the accepted standard.

The reasons have not changed: sterilization requirements conflict (devices typically require terminal sterilization; pharmaceuticals may degrade under the same conditions), environmental controls differ (cleanroom classifications, HVAC requirements, contamination control protocols), and the regulatory audit burden of a fully integrated facility is operationally very difficult to manage.

What has changed is the scale and sophistication of outsourcing as a solution to these challenges. The growth of specialized CDMOs (Contract Development and Manufacturing Organizations) with combination product expertise has given sponsors an alternative to building integrated capabilities in-house. A CDMO with established GMP pharmaceutical manufacturing and ISO 13485 device assembly capabilities can manage the integration challenges on behalf of a sponsor — including the interface between the two facilities, the supply chain coordination, and the quality management alignment.

This model introduces its own complexities — multi-party quality agreements, supply chain risk management, technology transfer — but for many sponsors, particularly those developing combination products as part of a broader portfolio rather than as a core manufacturing competency, it is a more pragmatic path than building fully integrated in-house capabilities.

Material compatibility remains one of the most technically demanding aspects of combination product development. Drug–polymer interactions, leachables and extractables from device components, the stability of pharmaceutical agents in contact with device materials over extended periods — these require systematic study from early development, not as an afterthought. Regulatory submissions increasingly expect comprehensive extractables and leachables data, and gaps in this area have caused approval delays and post-market complications.

Clinical Development: No Longer the Easier Path

In 2012, we characterized clinical development as one of the segments "eased" by the drug–device merger — the argument being that clinical evaluation could leverage the established pharmaceutical trial infrastructure.

That characterization no longer holds. Clinical development for combination products has become one of the most demanding aspects of the regulatory pathway.

The core challenge is that a combination product must demonstrate the performance of both components — and their interaction — within a single clinical program. Efficacy and safety of the pharmaceutical agent must be established. The performance of the device component must be demonstrated under real-world conditions of use. And the interaction between the two — whether the device affects drug delivery, pharmacokinetics, or user behavior in ways that influence clinical outcomes — must be characterized.

Usability and human factors data, once collected outside the clinical trial, are now expected to be integrated into the clinical evidence package. For self-administration devices, this means studying not just whether the product works, but whether patients — with varying levels of health literacy, dexterity, and prior device experience — can use it correctly in their own homes.

Real-world evidence generation post-approval is increasingly a regulatory expectation, not just a commercial aspiration. For combination products with extrapolated indications, new patient populations, or novel delivery mechanisms, post-marketing studies that capture device performance and patient outcomes in routine clinical practice are becoming part of the approval conditions.

The Digital Dimension: What 2012 Could Not Anticipate

Perhaps the most significant development since 2012 is the emergence of digitally integrated combination products as a distinct and rapidly growing category.

Connected inhalers that measure dose delivery and adherence. Wearable patch injectors controlled via smartphone applications. Implantable drug delivery systems with remote monitoring capabilities. Combination products that generate continuous streams of patient data, transmit it wirelessly, and incorporate it into treatment algorithms — sometimes in real time.

These products introduce regulatory, engineering, and quality challenges that have no precedent in the traditional combination product framework. Software as a Medical Device (SaMD) requires regulatory classification and validation in its own right. Cybersecurity is a lifecycle concern, not a one-time approval requirement — software updates, patch management, and vulnerability monitoring must continue throughout the product's commercial life. Data privacy and interoperability with healthcare information systems introduce regulatory and legal dimensions that neither pharmaceutical nor medical device regulations were designed to address.

The regulatory frameworks are catching up, but the gap between product innovation and regulatory guidance remains significant. Organizations developing digitally integrated combination products are, in many cases, navigating terrain for which clear precedent does not yet exist — which demands both regulatory sophistication and a proactive engagement strategy with regulators.

The Strategic Case: Stronger Than Ever

Despite the intensification of every challenge we identified in 2012, the strategic case for combination products has not weakened. If anything, it has strengthened.

The commercial logic is compelling. In crowded therapeutic markets — where biologic drugs face biosimilar competition and differentiation is increasingly difficult to achieve on pharmacology alone — the delivery system has become a genuine source of competitive advantage. A drug that is easier to self-administer, more reliably delivered, better tolerated, and digitally connected to the prescriber's monitoring system is a meaningfully better product, not just a marginally more convenient one.

Regulatory exclusivity associated with combination product innovation provides periods of market protection that are difficult to replicate through formulation changes alone. And the patient adherence benefits of well-designed combination products translate into better outcomes data — which increasingly matters for payer access and reimbursement decisions.

The business case for combination products — product differentiation, lifecycle extension, market access, patient outcomes — is as strong today as it was in 2012. The complexity of execution has grown proportionately. The organizations that succeed are those that plan for that complexity from the earliest stages of development, engage the right expertise across regulatory, engineering, quality, and clinical domains, and treat the integration challenges as a core part of their development strategy rather than an operational afterthought.

Conclusion: The Same Verdict, A More Complex World

In 2012, we concluded that the balance of risks and benefits favored integration in drug–device combination products. Thirteen years later, that verdict stands — but with a clearer understanding of what it actually requires to execute successfully.

The regulatory burden is heavier. The quality management demands are more complex. The engineering challenges have multiplied with the emergence of digital health integration. The clinical evidence requirements have expanded. The post-market obligations are more substantial.

And yet the products are more clinically powerful, the commercial opportunity is larger, and the patient impact — in therapeutic areas where biologic delivery, adherence, and real-time monitoring can make a genuine difference to outcomes — is more significant than ever.

For sponsors navigating this space, the lesson of the past decade is clear: the complexity of combination product development is not a reason to avoid it. It is a reason to approach it with the right expertise, the right partners, and a regulatory and operational strategy that is integrated into the program from day one.

---

Genelife Clinical Research supports combination product development across regulatory strategy, clinical trial execution, quality management coordination, and post-marketing surveillance. To learn more, visit genelifecr.com.

This article is an update to our original 2012 perspective by our ex colluge Dr. Ashish Indani, Head of Clinical Operations, Genelife Clinical Research.(The Challenges with Drug/Device Combination Products; 2012)

Related Insights

Our expertise in Medical Devices

Innovations Shaping the Future of Clinical Trials: Genelife Perspective

CDSCO Approval Process for Clinical Trials in India: Complete Guide

Post-Marketing Surveillance for Biosimilars: Why Approval Is Just the Beginning

 For most pharmaceutical products, regulatory approval marks the culmination of years of development work. For biosimilars, it marks a transition — from a controlled development environment to the far more complex, unpredictable world of real clinical practice. What happens after approval is not a regulatory formality. It is one of the most consequential phases of a biosimilar's lifecycle.

Post-marketing surveillance (PMS) is the mechanism by which that transition is managed. And for biosimilars specifically, it carries a weight that has no parallel in small-molecule drug development.

Why Biosimilars Demand a Different Post-Marketing Standard

To understand why post-marketing surveillance matters so much for biosimilars, it helps to start with what makes biologics fundamentally different from conventional drugs.

Small-molecule generics are chemically synthesized. They are structurally identical to their reference products — same molecule, same pharmacology, same behavior. Their generic approval pathway rests on this chemical equivalence, and the post-marketing obligations that follow are correspondingly straightforward.

Biosimilars are different. They are derived from living biological systems — cell lines, fermentation processes, complex manufacturing environments — and no two biological manufacturing processes produce precisely identical molecules. The comparability framework that governs biosimilar development is designed to demonstrate that these differences are not clinically meaningful. But it cannot eliminate the differences entirely.

This has two important implications for post-marketing surveillance.

First, the pre-approval clinical dataset for a biosimilar is, by design, smaller than what would be generated for a novel biologic. The entire rationale for the abbreviated development pathway is that comparability data — analytical, pharmacological, and clinical — reduces the evidentiary burden required before approval. But a smaller pre-approval dataset means a more limited window into rare adverse events, long-term safety signals, and population-specific responses. Post-marketing surveillance fills that window.

Second, immunogenicity — the tendency of biological molecules to trigger immune responses — is a concern that cannot be fully characterized in a pre-approval study. Anti-drug antibody development may emerge months or years into treatment. Its clinical consequences can range from inconsequential to serious, including loss of efficacy or, in rare cases, significant safety events. Only a robust post-marketing pharmacovigilance system, operating over meaningful time horizons, can adequately characterize this risk.

The Regulatory Framework in India

In India, post-marketing surveillance for biosimilars is governed under the Guidelines on Similar Biologics, jointly issued by the CDSCO and the Department of Biotechnology (DBT). The framework has strengthened considerably in recent years, with increasing alignment to international pharmacovigilance standards established by the US FDA, EMA, and WHO.

The core regulatory obligations are structured, time-bound, and non-negotiable — but the most sophisticated sponsors treat them not as a compliance floor, but as a strategic framework for lifecycle management.

The Core Components of a Biosimilar PMS Program

Pharmacovigilance System Infrastructure 

The foundation of any post-marketing surveillance program is a functioning pharmacovigilance system. For biosimilar manufacturers in India, this means establishing a Pharmacovigilance System Master File (PSMF), appointing a qualified safety officer, and building the operational infrastructure to detect, assess, and report adverse events in a timely and reliable manner.

In practice, this is more demanding than it sounds. Adverse event detection depends heavily on healthcare professional awareness and reporting behavior — both of which remain inconsistent in India's healthcare environment. Under-reporting is a well-documented challenge, and its consequences for biosimilars are particularly significant: rare but serious adverse events, or patterns of immunogenicity, may not surface in spontaneous reporting systems at the volumes needed to generate reliable safety signals.

Building a pharmacovigilance system that actively addresses this — through healthcare professional education, structured data collection channels, and proactive signal detection — is a meaningful operational investment, and one that distinguishes serious market participants from those treating PMS as a box-ticking exercise.

Periodic Safety Update Reports (PSURs)

India's regulatory framework requires PSUR submissions every six months for the first two years post-approval, and annually for the two years following. These reports are not simply summaries of adverse event counts. A well-constructed PSUR integrates safety data from all available sources — spontaneous reports, Phase IV studies, global pharmacovigilance databases, published literature — with a rigorous benefit-risk evaluation and signal analysis.

For sponsors running global biosimilar programs, PSURs also need to reflect the international safety picture — incorporating data from other markets where the product is approved and capturing any signals that have emerged globally. The increasing harmonization between India's PSUR requirements and international standards makes this integration more straightforward than it once was, but it still requires proactive planning and a pharmacovigilance infrastructure that can aggregate and analyze data across sources.

Phase IV Post-Marketing Studies

In many cases, the CDSCO requires Phase IV studies as a condition of biosimilar approval. These studies serve a specific evidentiary purpose: to evaluate long-term safety and immunogenicity in real-world patient populations that are broader, more diverse, and less carefully selected than those enrolled in pre-approval clinical trials.

Phase IV studies are particularly important in two scenarios. The first is where the pre-approval clinical dataset was limited in size or duration — which, given the abbreviated development pathway, is not uncommon. The second is where approval was granted on the basis of indication extrapolation. When a biosimilar is approved for indications beyond those directly studied in clinical trials, post-marketing data in those extrapolated indications becomes part of the ongoing evidence base for the product's benefit-risk profile.

Designing Phase IV studies that are scientifically meaningful, operationally feasible, and aligned with regulatory expectations requires the same rigor as pre-approval clinical development — not a scaled-down version of it.

Risk Management Plans

A Risk Management Plan (RMP) is a structured document that identifies known and potential risks associated with the biosimilar, specifies the pharmacovigilance activities designed to characterize those risks, and outlines the risk minimization strategies in place.

The critical characteristic of an RMP is that it is a living document. It evolves as new safety data emerges — from PSURs, from Phase IV studies, from global pharmacovigilance signals — and is updated accordingly. A biosimilar whose post-marketing safety profile remains clean will have a different RMP at year five than it did at approval. A biosimilar that generates unexpected immunogenicity signals will require a more active RMP with enhanced monitoring and potentially additional risk minimization measures.

Managing the RMP lifecycle proactively — rather than reactively — is a marker of pharmacovigilance maturity, and increasingly a point of regulatory scrutiny.

Traceability and Product Identification

Traceability is a challenge specific to the biosimilar context, and its importance cannot be overstated. Unlike small-molecule generics, where substitution between products is routine and largely inconsequential, biosimilars involve the real possibility that adverse events — particularly immunogenicity — may be product-specific rather than class-specific. If a patient develops anti-drug antibodies, it matters whether they were receiving one manufacturer's product or another's.

This makes accurate product identification — by brand name and batch number — in prescriptions, medical records, and adverse event reports an operational necessity. In India's healthcare environment, where prescribing and dispensing practices are highly variable, ensuring this level of traceability requires deliberate effort: education of healthcare professionals, pharmacy-level protocols, and patient-level documentation.

Immunogenicity Monitoring

Immunogenicity monitoring deserves particular emphasis because it is both the most biosimilar-specific risk and one of the most difficult to characterize adequately in pre-approval studies.

Post-marketing immunogenicity monitoring involves detecting the development of anti-drug antibodies (ADA), assessing whether those antibodies are neutralizing (i.e., capable of reducing or eliminating drug activity), and evaluating the clinical consequences — loss of efficacy, adverse reactions, or both. The monitoring program must be sustained over meaningful time periods, because ADA development can occur months or even years into treatment.

The analytical and clinical complexity of immunogenicity monitoring means it requires specialized expertise — in assay development and validation, in clinical data interpretation, and in understanding the regulatory standards for what constitutes an immunogenicity signal that warrants regulatory action.

The Role of PvPI and Real-World Evidence

India's Pharmacovigilance Programme of India (PvPI) is the national system for collecting and analyzing adverse drug reaction reports. Biosimilar manufacturers are expected to actively collaborate with PvPI — contributing data, participating in signal detection activities, and responding to regulatory requests.

Beyond the formal PvPI framework, real-world evidence (RWE) is playing an increasingly important role in the post-marketing biosimilar landscape globally. RWE — drawn from electronic health records, claims data, patient registries, and observational studies — can provide insights into biosimilar performance that neither pre-approval clinical trials nor spontaneous adverse event reporting can generate. It captures treatment patterns, switching behavior, long-term outcomes, and safety signals across large, heterogeneous populations.

In India, the RWE infrastructure is still developing, but the regulatory and scientific appetite for real-world data is growing. Sponsors who invest in structured real-world evidence generation — rather than waiting for the infrastructure to mature around them — will be better positioned both regulatorily and commercially.

The Strategic Dimension: PMS as a Competitive Differentiator

It is tempting to view post-marketing surveillance purely through a compliance lens — a set of obligations to be fulfilled on the path to maintaining marketing authorization. This is a strategically limited view.

In a market where multiple biosimilars of the same reference product compete for prescriber and payer confidence, post-marketing safety and efficacy data is a differentiating asset. A biosimilar with a clean, well-documented post-marketing safety record — backed by robust pharmacovigilance infrastructure and transparent PSUR reporting — builds trust with prescribers, payers, and patients in a way that approval alone cannot.

Conversely, a pharmacovigilance failure — a missed safety signal, a delayed PSUR, a traceability breakdown that prevents adverse events from being linked to the right product — can have consequences that extend far beyond regulatory sanction. In a therapeutic area like oncology or autoimmune disease, where patients are often on long-term biologic therapy, prescriber confidence is hard to earn and easy to lose.

The organizations that treat PMS as a strategic investment rather than a compliance cost are the ones that build durable market positions. And the ones that engage experienced partners for pharmacovigilance and post-marketing study management from the outset — rather than treating it as an afterthought — are the ones that execute that strategy successfully.

Conclusion

Post-marketing surveillance is not the end of biosimilar development. It is the phase in which the evidence base for a biosimilar is most continuously tested — by real patients, real clinical practice, and a regulatory system that expects ongoing accountability for safety and efficacy.

India's regulatory framework for biosimilar PMS has matured significantly, and its alignment with global standards is increasingly robust. For sponsors, this means both higher expectations and a clearer roadmap. The organizations that build their PMS infrastructure with the same rigor they apply to pre-approval development — and that engage with pharmacovigilance as a strategic function rather than a regulatory obligation — are the ones best positioned to build lasting value in the biosimilar market.

At Genelife Clinical Research, our post-marketing services span pharmacovigilance system setup, PSUR preparation, Phase IV study design and execution, RMP management, and real-world evidence generation. We work with biosimilar sponsors to ensure that the transition from approval to market is managed with the same precision as the development program that preceded it.

---

To learn more about Genelife's post-marketing and pharmacovigilance capabilities, visit genelifecr.com.

Related Insights

What is Pharmacovigilance  

Real World Evidence (RWE) in Clinical Research 

Phases of Clinical Trials Explained

Biosimilar Regulation in India

Our Services for Biosimilars

Biosimilar Regulation in India: Evolving Landscape and Current Perspectives

The global biosimilar market is no longer a niche segment of pharmaceutical development. It has become a strategic priority for companies of all sizes — driven by patent cliffs on blockbuster biologics, mounting pressure on healthcare systems to improve access, and the maturation of regulatory frameworks that have made development more predictable and commercially viable than ever before.

India sits at the center of this shift. Once viewed primarily as a cost-efficient manufacturing destination, India has steadily built the scientific, regulatory, and commercial infrastructure to become a genuine force in the global biosimilar ecosystem. For sponsors navigating a biosimilar program — whether targeting the Indian market, regulated markets such as the US and EU, or both — understanding how India's regulatory framework has evolved is not just a compliance exercise. It is a strategic necessity.

From Compliance-Driven to Science-Driven: A Decade of Regulatory Maturation

When India introduced its "Guidelines on Similar Biologics" in 2012 — jointly issued by the CDSCO (Central Drugs Standard Control Organization) and the DBT (Department of Biotechnology) — the framework was a significant first step, but it carried the limitations of its era. Clinical trial requirements were heavy. Animal studies were routine expectations rather than risk-based decisions. Extrapolation of indications was poorly defined, adding uncertainty and cost to development programs.

The 2016 revision addressed several of these gaps, and the years since have seen continued regulatory refinement, increasing alignment with global standards set by the US FDA, EMA, and WHO.

The result is a framework that has shifted from being primarily compliance-driven to being genuinely science-driven and risk-based. That distinction matters enormously for sponsors and developers, because it fundamentally changes how a biosimilar program is planned, resourced, and executed.

What Has Actually Changed — and Why It Matters

Analytical Similarity Is Now the Foundation

The single most consequential shift in biosimilar development — globally and in India — is the elevation of analytical characterization to the center of the development strategy.

A decade ago, demonstrating biosimilarity relied heavily on clinical trial data. Analytical tools were important, but the evidentiary burden rested disproportionately on large, expensive comparative efficacy trials. Today, that hierarchy has inverted. State-of-the-art physicochemical and biological characterization — structural analysis, functional assays, receptor binding studies — now forms the backbone of a biosimilarity demonstration.

For sponsors, this is a fundamentally more efficient development model. When analytical similarity is established with high scientific rigor, it creates the evidentiary foundation on which regulators can grant concessions elsewhere in the development program — including, in appropriate cases, the waiver of confirmatory Phase III efficacy trials.

This does not mean clinical development is optional. It means it is now sized to the residual uncertainty that analytical and PK/PD data cannot resolve — which, for well-characterized molecules with a well-understood mechanism of action, can be considerably less than a full Phase III program.

The Clinical Burden Has Been Rationalized

Under India's current framework, comparative pharmacokinetic (PK) studies remain mandatory. Where reliable pharmacodynamic (PD) biomarkers exist, PD studies are conducted — and combined PK/PD studies are increasingly accepted. These studies, conducted in appropriate populations, provide a rigorous comparability assessment without the scale and cost of large Phase III programs.

The critical shift is the conditional waiver pathway for confirmatory efficacy trials. If analytical similarity is robust, if PK/PD comparability is convincingly demonstrated, and if the mechanism of action of the reference biologic is well understood, regulators now have the scientific basis to waive or substantially reduce the requirement for a large comparative clinical trial.

This is not a regulatory shortcut. It is a recognition that, for certain molecules under certain conditions, the clinical trial adds limited incremental information beyond what analytical and PK/PD data already establish. Understanding when and how to make that argument — and building the evidence package to support it — is a core strategic capability in modern biosimilar development.

Non-Clinical Requirements Have Been Rationalized Too

A parallel shift has occurred in the non-clinical space. Where animal studies were once routinely expected, the current framework adopts a genuinely risk-based approach. Comparative in-vitro studies — receptor binding assays and cell-based functional assays — are mandatory. In-vivo studies are required only where in-vitro models are insufficient to characterize a meaningful difference that could affect safety or efficacy.

For sponsors, this reduces development timelines and costs without compromising the scientific integrity of the comparability exercise. The key is designing in-vitro studies that are sufficiently sensitive and relevant to justify the decision on in-vivo requirements.

Extrapolation of Indications Is Now Clearly Permitted

One of the most commercially significant elements of India's current biosimilar framework is the explicit acceptance of indication extrapolation. If a biosimilar has demonstrated similarity to the reference biologic — analytically, pharmacologically, and clinically — it may be approved for additional indications of the reference product without conducting separate clinical trials in each indication, provided the scientific rationale is sound.

The basis for extrapolation rests on mechanism of action, receptor interaction, and the immunogenicity and safety profile of the molecule. When these factors support extrapolation, the commercial implications are substantial: access to a broader indication set at a fraction of the cost of indication-specific development programs.

This is an area where regulatory strategy and scientific planning intersect directly with business outcomes — and where experienced guidance can make a material difference to the scope of a program.

The Regulatory Pathway: Clearer, Faster, More Structured

The end-to-end regulatory pathway for biosimilars in India involves multiple authorities across development and commercialization stages. What has changed is not the number of steps — it is the clarity, predictability, and timeliness of the process.

The pathway moves from early R&D and clone development (overseen by the Institutional Biosafety Committee), through preclinical approvals and data review by the Review Committee on Genetic Manipulation (RCGM), to clinical trial application and approval by the CDSCO under the DCGI. Manufacturing permissions for clinical trial batches sit with the State FDA; marketing authorization returns to the CDSCO; commercial manufacturing licensing reverts to State FDA.

What sponsors find significantly improved compared to a decade ago is the structured review mechanism at each stage, clearer timelines, and a more predictable engagement process with regulators. This matters not just for planning purposes, but for investor confidence and portfolio management — particularly for companies running simultaneous programs across multiple molecules or geographies.

Pharmacovigilance and Post-Marketing Obligations

Biosimilar approval is not the end of the regulatory journey. India's pharmacovigilance framework for biosimilars has strengthened considerably, and post-marketing obligations are a real part of the program lifecycle.

PSUR (Periodic Safety Update Report) submissions are required every six months for the first two years post-approval, and annually for the two years following. Phase IV post-marketing studies are required in many cases, with a focus on long-term safety and immunogenicity monitoring in real-world populations. These studies feed into India's Pharmacovigilance Programme (PvPI) and are increasingly informing real-world evidence generation for biosimilars.

For sponsors, the strategic implication is clear: post-marketing commitments need to be planned and resourced from the outset, not treated as an afterthought once marketing authorization is secured. The cost and operational complexity of pharmacovigilance obligations should be built into the program business case from day one.

India's Strategic Position in the Global Biosimilar Market

India's evolution as a biosimilar hub is the product of converging strengths: deep manufacturing capability, a skilled and growing scientific workforce, cost structures that are competitive globally, and a regulatory framework that is increasingly harmonized with international standards.

The implication of this last point is particularly significant. Indian companies developing biosimilars for regulated markets — the US, EU, and UK — can increasingly design global clinical programs that satisfy multiple regulatory authorities with a single evidence package, leveraging India's regulatory alignment to reduce duplication. At the same time, the Indian domestic market itself represents a substantial and growing opportunity, particularly in therapeutic areas like oncology, autoimmune diseases, endocrinology, and rare disorders where biologic therapies are underutilized due to cost.

The companies that will define India's next chapter in biosimilars are those that combine scientific rigor with regulatory sophistication — that understand not just how to develop a biosimilar, but how to build the evidence package that maximizes regulatory efficiency, supports indication extrapolation, and positions the product competitively across target markets.

What This Means for Your Biosimilar Program

The evolution of India's biosimilar regulatory framework has created genuine strategic opportunity — but realizing that opportunity requires more than scientific capability. It requires regulatory strategy that is integrated into program design from the earliest stages.

The decisions made at feasibility — which reference product, which analytical platform, which clinical design, which markets — have compounding consequences throughout the program lifecycle. A Phase I PK study designed without a clear view of the extrapolation strategy can leave evidence gaps that are expensive to fill later. An analytical characterization program that is not built around the evidentiary requirements for a Phase III waiver cannot retroactively support that argument.

This is where experienced clinical research partners add value that goes beyond execution. At Genelife Clinical Research, our biosimilar experience spans the full development continuum — from comparability study design and regulatory strategy to clinical trial execution, pharmacovigilance, and post-marketing study management. We work with sponsors to build programs that are scientifically rigorous, regulatorily efficient, and commercially strategic from day one.

Conclusion

India's biosimilar regulatory framework has undergone a genuine transformation over the past decade. The shift from a compliance-driven to a science-driven, risk-based approach has reduced development burden, improved regulatory predictability, and opened meaningful strategic pathways — including the potential for Phase III waivers and broad indication extrapolation — for sponsors who plan their programs with regulatory sophistication.

For the global biosimilar market, India is no longer just a manufacturing hub. It is a development partner of strategic importance. The organizations best positioned to capitalize on this are those that understand both the science and the strategy — and who choose development partners with the depth of experience to navigate both.

Genelife Clinical Research provides end-to-end biosimilar development support, from regulatory strategy and comparability study design through clinical execution and pharmacovigilance. To learn more, visit genelifecr.com.

Related Insights

What is Pharmacovigilance and Why It Matters in Clinical Trials

CDSCO Approval Process for Clinical Trials in India: Complete Guide

Learn more about our clinical research services for end-to-end clinical trial support.